1. No category

Emmetrope Inc.
La Canada, CA
Andrew Phillips, M.D.
President & CEO
• Developing a line of accommodating IOLs
• Broad coverage of restrained lens technology
3 Versions, same platform:
– Single optic: ActaLens
•
TM,
Clinical Study Phase, podium presentation at ESCRS 2014
– Dual Optic: ActaLens-Duo
– Shape Change Optic: ActaLens-SC
EMMETROPE
MECHANISM
MANUFACTURED
RESTRAINED
YAG
ACTIVATED:
1 MONTH CYCLOPLEGIA
EMMETROPE
RESTRAINT RELEASED
IMPLANTED
Total Axial Displacement, 10 Months Post-Implant
UBM (Cyclo-Pilo)
CrystaLens ®
ActaLens
CrystaLens
ActaLens ®
-.07 + .07 MM
+.48 +.09 MM
-0.4
EMMETROPE
-0.2
0
0.2
MM
0.4
0.6
0.8
ActaLens Movement
Pentcam HR Total Movement, 1 year
CrystaLens
ActaLens
ActaLens 0.37 + .10
CrystaLens 0.05 + .06
-0.1
0
0.1
0.2
0.3
MM
EMMETROPE
0.4
0.5
0.6
UBM of ActaLens at 10 Months
REICHERT UBM 35MhZ
Patient AV, male, 68 y/o, UCVA 20/20-2
Total axial movement 0.52 MM
16
°
Cyclopentalate 1%
EMMETROPE
31
°
Pilocarpine 2%
Estimated Accommodative Effect of Actalens: ~ .5D
axial shift alone may not be sufficient
as lens flexes from observed 10 to 24 degrees
24 degrees
(Pilocarpine)
10 degrees
(Cyclopentalate)
EMMETROPE
ActaLens-SC ( Shape-Change)
• Same platform and hinge design as fixed optic version
– Again, .4 MM movement and 10 to 15 degrees flexion
expected
• 2 layer lens. Base layer firmer silicone. Top layer of
softer silicone deforms over base layer as haptics flex.
EMMETROPE
ActaLens vs ActaLens-SC
Change in optical power for flexion of haptics from
10 to 24 degrees
Fixed-optic design: ~ .5D
EMMETROPE
Dual-layer shape change: 4D +
Finite Element Analysis
ActaLens-SC
EMMETROPE
Summary
• ActaLens
– UBM, Pentacam, and Lenstar proven movement
– Novel, capsule-independent mechanism
• Actalens-Duo: Dual optic design
– Increases accommodative effect
• Actalens-SC
– Using same clinically tested platform from first
generation Actalens, > 5 D total pharmacological
accommodation expected, lens power
independent.
– Objectively measurable accommodation greater
than 2 D will be crucial to success.
EMMETROPE
Evaluation of Movement at 20
Months
• Independent analysis
– VIROS, N. Hirnshall MD, PhD, Findl, O, MD
• Lenstar PCI measurement of cyclo/pilo
axial shift at 20 months confirms
movement:
• .46 MM + .13 total movement of ActaLens
• no axial shift in control group
EMMETROPE
Emmetrope Inc.
La Canada, CA
Andrew Phillips, M.D.
President & CEO
• Developing a line of accommodating IOLs
• Broad coverage of restrained lens technology
3 Versions, same platform:
– Single optic: ActaLens
•
TM,
Clinical Study Phase, podium presentation at ESCRS 2014
– Dual Optic: ActaLens-Duo
– Shape Change Optic: ActaLens-SC
EMMETROPE